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Aim: To assess the effectiveness of catheter directed thrombolysis (CDT) in the treatment of acute graft
occlusion.
Methods: Tissue prothrombin activator (rt-PA) was the sole agent used for thrombolysis. This was infused
through a 4F straight 65 cm catheter placed under ultrasound guidance. Following a pre-CDT angiogram,
a catheter was placed just proximal to the distal anastomosis. An infusion of rt-PA was given over 24 h.
An assessment of acute clinical success, limb salvage rates, patency rates and complication rates were
made over a period of one year.
Results: 80% (20/25) of grafts were successfully reopened immediately. 4/5 (80%) of the unsuccessful CDT
cases required amputation within a few weeks. 60% (12/20) of successful CDT cases had an underlying
stenotic lesion which required angioplasty. Limb salvage rate was 72% (18/25) at 12 months. There was no
CDT related mortality. Secondary patency rate at 9 months was 76% (13/17).
Conclusion: CDT can achieve reasonable results in this group of challenging patients and may be seen as
a useful accessory in the vascular toolkit. However, precise indications for its use need further
clariﬁcation.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The precise indication in clinical practice for thrombolytic
therapy in the management of acute limb ischaemia remains
equivocal. The theoretical advantages are clear; they include the
potential to reopen occluded vessels or grafts in situ, occluded
collaterals and run-off. Further advantages include the unmasking
of underlying anatomical pathology which may be amenable to
endovascular or limited surgical intervention, limiting the trauma
to endothelium and the gradual reintroduction of oxygen rich
blood thus minimising reperfusion injuries. It has been shown that
thrombolytic agents have the potential to limit skeletal muscle
damage after critical ischaemia and may be due to controlled
reperfusion of the microvasculature.1 The main concern surrounds
the reported long-term patency rates and the risk of systemic
haemorrhage especially intra-cerebral haemorrhage. This argu-
ment may be justiﬁed as the initial use of intravenous (IV)
thrombolysis for peripheral arterial occlusions (PAO) was followediqui).
ciates Ltd. Published by Elsevier Ltby an extraordinarily high rate of bleeding complications,2,3 with
a reported mortality of 7%. Reports followed suggesting that intra-
arterial (IA) thrombolysis may be a better modality of treatment for
PAO with reduced risks of systemic bleeding.
The technique of IA catheter directed thrombolysis (CDT) was
reported by Dotter et al. in 1974.4 It was followed by widespread
enthusiasm in the published literature during the 1980s. Early
indications were that CDT was safe, offered a better limb salvage
and mortality rate compared to surgery in the treatment of acute
lower limb ischaemia (deﬁned as symptom onset of less than 14
days).5 Bleeding complications weremore common in CDT patients
but were relatively minor. In the aforementioned meta-analysis,
the incidence of cerebrovascular accidents appeared to be 10
times more likely in surgical revascularizations.6 Berridge et al.7
had more trials available to them in their meta-analysis and
found no signiﬁcant difference in mortality or limb salvage rates
between surgery and thrombolysis, but a slightly higher rate of
signiﬁcant bleeding complications in the thrombolysis group.
Despite these ﬁndings, the use of IA thrombolysis in the treatment
of acute limb ischaemia is not widely accepted. Some surgeons
never consider it as an option. Concerns about its efﬁcacy, cost,
safety and long-term patency rates in reopened grafts remain.d. All rights reserved.
Table 1
Demographics for patients undergoing CDT with success rates.
Gender CDT success rate
M: 16 (64%) 12/16 (75%)a
F: 9 (36%) 8/9 (88.8%)
Age at presentation (yrs): Mean ¼ 65.56
60: 8/25 (32%) 7/8 (87.5%)a
>60: 17/25 (68%) 13/17 (76.5%)
Graft age (mths): Mean ¼ 20.04
12: 11/25 (44%) 9/11 (81.8%)a
>12: 14/25 (56%) 11/14 (78.6%)
Symptom duration (days) Mean ¼ 6.56
<14: 22/25 (88%) 18/22 (81.8%)a
14: 3/25 (12%) 2/3 (66.6%)
Diabetes: 9/25 (36%)
Hypertension: 15/25 (60%)
Ischaemic heart disease: 7/25 (28%)
Renal failure: 1/25 (4%)
CDT total n (%) 25 (100)
Unsuccessful 5/25 (20)
Successful 20/25 (80)
No stenosis 8/20 (40)
Stenosis 12/20 (60)
Proximal 4/12 (33.3)
Distal 8/12 (66.6)
a Not statistically signiﬁcant.
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lysed in the meta-analysis. However it was withdrawn by the US
food and drug agency (FDA) in 1999 because of the potential to
transmit infectious agents. Streptokinase has the disadvantage of
being antigenic and can only be used once per patient. Moreover,
both urokinase and streptokinase are relatively non-ﬁbrin speciﬁc,
acting on both circulating and ﬁbrin bound prothrombin. In theory,
this non-speciﬁcity may increase the risk of causing systemic ﬁbri-
nolysis and bleeding. There has therefore been a shift to the
genetically engineered and relatively more “ﬁbrin-speciﬁc” agents.
When used intra-arterially, these caused less systemic complica-
tions, decreased time to lysis and had lower dosage requirements.8,9
We have undertaken a retrospective analysis to review the
results of CDT in our patients because initial inspection suggests
that CDT should be considered more seriously as a viable and
sometimes better alternative to surgical intervention.
2. Materials and methods
This is a retrospective analysis of patients treated with CDT at the St Peters
hospital, Chertsey from February 2005 to April 2008. The authors mainly use
thrombolysis in the management of failed or failing synthetic grafts. The interval
corresponds to the time in which the same surgeon and radiologist have been
working together on CDT. Recombinant tissue prothrombin activator (rt-PA) was the
only agent used, and the same protocol for CDT has been adhered to during the
period analysed. A thorough search of the computerised databases of the hospital
(PACS, PAS and angiography suite records) was made using the keywords “throm-
bolysis” and “grafts” to identify all the patients that had undergone CDT in the
hospital. Twenty three patients were identiﬁed (25 limbs/grafts). Therewere twenty
one polytetraﬂouroethylene (PTFE) femoro-popliteal grafts, three PTFE ilio-popliteal
grafts, and one silver coated Dacron axillo-popliteal graft. The case notes were
reviewed and demographic data extracted. These included age, sex, duration of
symptoms prior to lysis, and signiﬁcant co-morbidities (hypertension, Diabetes
Mellitus, renal failure and cardiac disease). The usual selection criteria for the use of
thrombolysis in our hospital are acute symptoms of graft occlusion (symptoms less
than 14 days) with an SVS/ISCVS (Society for vascular surgery/International society
for cardiovascular surgery) grade of II.10 However all patients that had undergone
thrombolysis were included in this review including 2 patients that had symptoms
lasting three weeks and four weeks. Patients with irreversible limb ischaemia and
those with absolute contraindications to thrombolysis (Stroke, intracranial tumours,
gastrointestinal haemorrhage in the last three months) were not offered throm-
bolysis. Follow up data was then extracted. Clinical ﬁndings and duplex scan results
were obtained at approximately 3 months, 6 months and 12 months.
2.1. CDT procedure
The regime used for thrombolysis in our hospital was developed and stand-
ardised prior to the period of study. Fully informed consent was obtained before the
procedure. A baseline haemoglobin estimation, white cell count, platelet count,
clotting screen and renal function tests was obtained. Serum was saved for blood
grouping. The patient was transferred to the angiography suite for the procedure.
Intravenous antibiotics were given and maintained for the duration of thrombol-
ysis. Prior to thrombolysis an angiogram was performed to conﬁrm the graft
occlusion and assess the outﬂow. Under ultrasound control, the thrombosed graft
was punctured in an antegrade manner just below the proximal anastomosis. A
guide wire and 4F straight 65 cm catheter (Cook, Bloomington, USA) was intro-
duced with the distal end of the catheter lying just proximal to the distal anasto-
mosis. If the popliteal artery was occluded then angioplasty was undertaken
immediately in an attempt to open the popliteal artery. This angioplasty included
the distal anastomosis. If the popliteal artery was patent, immediate angioplasty
was not undertaken. The rationale for immediate angioplasty of the thrombosed
popliteal artery was that limb salvage was expected to be poor in the presence of
both femero-popliteal graft occlusion and popliteal artery occlusion. It was
important to re-establish popliteal artery ﬂow to improve the likelihood of both
graft and limb salvage. Recombinant tissue plasminogen activator (rt-PA) was used
for thrombolysis. A bolus dose of 5 mg rt-PA was given via the catheter over 5 min
and maintained with an infusion of rt-PA at 1 mg/h. Analgesia was prescribed and
the patient warned that there will be pain on reperfusion. The patient was observed
in the surgical high dependency unit and the infusion continued for 24 h at which
point a follow up angiogram was undertaken. During this angiogram, any under-
lying stenosis at the distal anastomosis underwent angioplasty. Lysis was usually
complete in 24 h. The recommendation by Khosla et al.11 in their study was never to
exceed a total rt-PA dose of 100 mg as bleeding complications were more likely to
occur then. On extraction of the catheter, an Angioseal (St Jude Medical, Zaventem,
Belgium) device was used to close the puncture site. The patients were thencommenced on intravenous heparin (24,000 units per 24 h). Patients with re-
occluded grafts were started on warfarin (INR range 2.0e2.5).
2.2. Outcome measures
There were seven main areas examined by this review. These were: 1) acute
clinical success rate deﬁned as the number of times thrombolysis was clinically and
radiologically successful in reopening the occluded graft. Radiological success was
deemed to have taken place if 90% of the graft lumen was open, with adequate run-
off. This included the use of angioplasty pre- or post-thrombolysis. This radiological
success was also conﬁrmed clinically with a viable, non threatened limb and Doppler
signal in at least one of the distal run-off vessels. 2) Underlying stenosis rate: the
number of times a signiﬁcant stenosis was unmasked by thrombolysis, requiring
angioplasty. 3) Primary assisted patency rate: Patency of the target vessel with
additional angioplasty or surgery within two weeks of initial CDT. This includes any
thrombolysis repeated within two weeks. Patency rates were recorded at 3, 6 and 9
months. 4) Secondary patency rate: If any extra intervention (thrombolysis, angio-
plasty or surgery) was required to keep the graft open after twoweeks, then this was
considered secondary patency. 5) Complications: These were vascular or non-
vascular. Vascular complications were considered minor if they could be managed
by conservative means. Those requiring surgical/endovascular intervention or blood
transfusions were considered major. Compartment syndrome was documented as
a complication if the patient developed sufﬁcient symptoms to require a fasciotomy
after CDT. 6) Limb salvage rate: The number of limbs saved as a result of CDT. 7)
Mortality rate: Mortality was attributed to CDT if patient died of a CDT related
complication. The overall mortality ratewas then noted at 30 days and at 12months.
2.3. Statistical analyses
This was carried out using graph-pad prism 5. Differences between demo-
graphic factors and graft related variables were identiﬁed using Fischer’s exact test,
with a two tail p value (alpha < 0.05) where appropriate.3. Results
23 patients (25 limbs) underwent CDT for acute infra-inguinal
prosthetic graft occlusions. 64% were men. Acute clinical success
was achieved in 20 grafts. Of the 5 that failed CDT, 4 had an ampu-
tation because of non-reconstructable distal disease. The remaining
patient was managed conservatively and remained mobile and
asymptomatic during the course of the study. The patient demo-
graphics with CDT success rates are shown in Table 1. There was no
statistical difference shown in the success rate of CDT, between the
different groups compared. In total, CDT was successful in 80% of
cases. An underlying stenosis, requiring angioplasty was uncovered
Table 2
Signiﬁcant complications following CDT.
Complications Rate
Infection 1/25 (4%) Graft infection after above
Knee amputation (AKA)
Bleeding
Major 4/25 (16%) Required blood transfusions
(2 after thrombectomy and surgical
vascular access respectively)
Minor 6/25 (32%) Minor haematomas
Compartment
syndrome
2/25 (8%) Had fasciotomies
Renal dysfunction 1/25 (4%) Mild. Noted in one patient with diabetes,
Ischaemic heart disease and hypertension
Table 4
Limb salvage rate and mortality.
1 month 12 months
Limb Salvage rate 21/25 (84%) 18/25 (72%)
Mortality 1/25 (4%) 2/25 (8%)
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stenosis (66.6%) and there was no intra-graft stenosis noted.
Four main complications were noted during the period of this
study. These were infection, bleeding, compartment syndrome and
renal dysfunction. There were no observed episodes of embolic
phenomena. One graft infection was noted after CDT failure
resulting in an above knee amputation (AKA). This patient had an
axillo-popliteal bypass graft and a previous aorto-bifemoral graft.
When CDT failed to reopen the graft, an AKA was performed.
Unfortunately the patient developed an infection in the residual
graft and expired as a result of sepsis. We do not feel this infective
episode was a result of CDT. Bleeding was the most common
complication. These were mainly haematomas at the site of the
catheter puncture. In 4/25 (16%) patients, the patient dropped their
haemoglobin enough to require a blood transfusion. These patients
were classiﬁed as having major complications. One of these
patients had surgery to obtain access, while the other had a popli-
teal thrombectomy to obtain distal run-off after CDT. Two patients
developed a compartment syndrome, requiring fasciotomies. There
was one patient with a urea of 21 mg/dL and creatinine of 151 mg/
dL. This patient had associated risk factors for renal disease
(Table 2) and developed a signiﬁcant haematoma after CDT. His
renal dysfunction resolved on blood transfusion and rehydration.
The patency rates are shown in Table 3. Primary assisted patency
rate was 15/18 (83.3%) at 3 months. This was followed by a gradual
decline to 41% at 9months. However, the secondary patency ratewas
76.5% at 9 months. Secondary patency was maintained by repeated
thrombolysis and angioplasty  stent placement as required. There
were three repeat CDT episodes in three different grafts, which
successfully re-established patency over the course of the 9 months.
Table 4 shows limb salvage rates. In four of ﬁve patients, failure
of thrombolysis resulted in amputation within a few weeks, giving
a limb salvage rate of 84% at one month. 3 more limbs were lost
over the year, giving a limb salvage rate of 72% at one year. The two
deaths recorded during the course of the study occurred within 6
weeks of CDT, and followed surgery for re-occluded limbs. The
mortality rate was 8% at one year.4. Discussion
In infra-inguinal arterial occlusive disease requiring bypass
grafts, autogenous vein grafts remain the gold standard to which
alternatives may be compared. It has a reported secondary patencyTable 3
Patency rates.
1 assisted Patency 2 Patency
At 3 months 15/18 (83.3%) 16/18 (88.9%)
At 6 months 11/17 (64.7%) 15/17 (88.2%)
At 9 months 7/17 (41.2%) 13/17 (76.5%)rate of over 80% and 75% at one and ﬁve years respectively.12
However, in many cases surgeon preference or lack of adequate
vein conduit leads to the use of synthetic grafts. Synthetic grafts
have an acceptable but slightly inferior long-term patency rate,
especially in bypasses to the popliteal artery proximal to the knee
joint. This difference in patency rates does not translate to any
signiﬁcant difference in limb salvage rates.13 A substantial number
of these failed synthetic grafts present with limb threatening
ischaemia (SVS/ISVS standards grade II) and is reported to occur in
approximately 78% of cases.14 Redo surgery can be difﬁcult in this
subset of patients, who are often poor surgical candidates. This
results in signiﬁcant morbidity and mortality. Any approach that
could potentially avoid surgery or limit its scope; provide accept-
able patency, morbidity and mortality rates, would be welcome.
We believe CDT provides a reasonable safe adjunct or alternative
in this subset of patients. As this is a retrospective study, we have
not been able to compare results of CDT in autogenous vein grafts
as this was not the practice of the surgeons at the time. However,
there is some literature to suggest the results of CDT are similar in
occluded autogenous veins, innate vessels as well as prosthetic
grafts.15 Our study continues to corroborate the high initial tech-
nical success rate which has been shown by other studies
(80%).15e18 In almost all cases when CDT was not successful, these
patients had un-reconstructable distal disease and proceeded to
amputation. CDT not only cleared the thrombus from grafts but also
demonstrated when the distal circulation could not be reopened as
a result of progressive distal disease. This often made management
decisions more straightforward.
One of the main criticisms of those that oppose the use of CDT is
the perceived incidence of serious haemorrhagic complications.
Cursory inspection would suggest that our degree of technical
success has been followed by a signiﬁcant bleeding complication
rate (16%). In all cases, these were bleeding at the puncture site.
There was a direct correlation between the size of incision made for
vascular access and the degree of bleeding. Adjunctive surgical
procedures accounted for 50% of post-CDT major bleeding
complications. Adjunct surgery should therefore be avoided where
possible. Revascularisation of critically ischaemic limbs is always
associated with the risk of compartment syndrome, no matter
which technique is used. This is demonstrated in our study which
shows the incidence of fasciotomies to be 8%. The only graft
infection associated with our study occurred after amputation
following CDT failure with infection in the residual graft which
needed to be removed subsequently. We do not believe this was
a direct complication of CDT. Pre-angiography antibiotic prophy-
laxis may minimise the risk of infection.
Though some other studies have suggested the maturity of
grafts was a factor in CDT success, especially in relation to patency
rates,19 no statistical difference was seen in both the immediate
technical success rates and secondary patency rates between the
subgroups examined in our study. As our study is quite small, this
may be a type II error. An underlying lesionwas unmasked in 60% of
cases, which is comparable to previous reports in comparable
studies.15,16,18 Dealing with these is crucial to the overall patency of
the grafts. Pedersen et al.20 suggested that the failure to ﬁnd an
underlying stenosing lesion was a poor prognostic indicator. The
most prevalent lesion in our study was a distal stenosis (66.6%),
which is in keeping with ﬁndings from other series and may be
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of proximal lesions too (33.3%) which occurred either in isolation or
in combination with a distal lesion. Interestingly, there were no
intra-graft lesions, which may suggest they play very little role in
the occlusion of prosthetic grafts. Brumberg et al.21 suggested that
low ﬂow within the graft may be a more important duplex
predictor of graft failure. Distal stenosis, peripheral progression of
atherosclerosis and signiﬁcant proximal stenosis (in order of
importance) would all lead to a low ﬂow state within the graft and
could be the ﬁnal common pathway of graft failure. Thus, surveil-
lance with duplex ultrasound and documentation of low slow rate
within the graft should play an important role in the management
of these grafts. Demonstration of a low ﬂowmay then suggest a role
for warfarin as suggested by Brumberg et al.21
As demonstrated in this study, angioplasty can be done
successfully for the graft associated stenosis, but distal disease is
often the cause of failure and eventual limb loss. Limb salvage was
72% at one year which is comparable to previous ﬁndings. However,
all of these had clearly progressive distal disease and it is unlikely
that these limbs could have been saved in any other way. With
careful patient selection, failed CDT would mean that patients are
inappropriate for any other limb saving procedure. Theoretically
CDT might prolong the time to complete outlet failure by opening
up thrombosed distal vessels, thus prolonging the time to limb loss.
This might be crucial in elderly patients where the loss of inde-
pendence from limb loss could be devastating.
The secondary patency rates in our study (76.5% at ninemonths)
are better than reported in other studies and we think this is due to
the aggressive attention paid to ensuring adequate run-off by
angioplasty during CDT.15,16,20 Patency was ensured by repeated
CDT  angioplasty  proximal stents as required over the ensuing
12months. Failure was always because of progressive distal disease
and two of these went on to lose their limbs. An analysis of the
long-term patency rate in this cohort of patients would be useful.
However, our study shows that CDT is not associated with the poor
patency rates previously reported. We suspect these rates will
continue to improve as techniques and use of CDT develops.
Furthermore patency rate on its own is argued to be a poormeasure
of success in limb reperfusion. As these occluded grafts initially
present with a threatened ischaemic limb, a better measure of
success would be limb salvage. It is clear that though some of the
grafts re-occlude after CDT limb loss is not inevitable. We feel that
CDT is able to prolong limb viability, even when the graft has re-
occluded.
The one year mortality rate in our group of patients was 8% (2/
25), but none of these deaths were directly related to CDT. One
patient died after surgery to re-vascularise his limb failed, and was
followed by multiorgan failure. The other would have died irre-
spective of any surgical intervention as he was unsuitable for
surgery and developed massive rhabdomyolysis when CDT failed.
Critical limb ischaemia is associated with a one year mortality rate
of over 25%22 and the above mentioned mortality rate in our group
of patients would therefore be acceptable. It is debateable whether
accepting a limb loss in the ﬁrst patient would have resulted in
a better mortality rate. Surgery is not without its risks and CDTmay
be a better alternative in some circumstances.
5. Conclusions
CDTcanachievereasonable results in thisgroupofdifﬁcultpatients
and should be seen as a useful accessory in the vascular toolkit.
However, the exact indications for its use need further clariﬁcation.
Ethical approval
None.Funding
Nil.
Author contribution
CUAI contributed to study design, data collection and analysis as
well as writing of the paper. MRSS contributed to analysis and
writing of the paper. LTG, JH, NB contributed towriting of the paper
and design.
Conﬂicts of interest
Nil.
Acknowledgements
Mr Kieran Dawson, Mr Martin Thomas.
References
1. Belkin M, Valeri R, Hobson RW. Intra-arterial urokinase increases skeletal
muscle viability after acute ischaemia. J Vasc Surg 1989;9:161e8.
2. Sherry S, Fletcher AP, Alkjaersigm N, Smyrniotis FE. An approach to intravas-
cular ﬁbrinolysis in man. Trans Assoc Am Physicians 1957;70:288e96.
3. Amery A, Deloof W, Vermylen J, Verstraete M. Outcome of recent thromboem-
bolic occlusions of limb arteries treatedwith streptokinase. BMJ 1970;4:639e44.
4. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low dose streptokinase.
Radiology 1974;111:31e7.
5. Results of a prospective randomized trial evaluating surgery versus throm-
bolysis for ischemia of the lower extremity. The STILE trial. Ann Surg
1994;220(3):251e66 (discussion 266e8).
6. Difﬁn DC, Kandarpa K. Assessment of peripheral intraarterial thrombolysis
versus surgical revascularization in acute lower-limb ischemia: a review of
limb-salvage and mortality statistics. JVIR 1996;7(1):57e63.
7. Berridge DC, Kessel DO, Robertson I. Surgery versus thrombolysis for initial
management of acute limb ischaemia (Review). Cochrane Database of Syst Rev
2002;1. doi:10.1002/14651858.CD002784. Art. No.: CD002784.
8. Mahler F, Schneider E, Hess H. Recombinant tissue plasminogen activator
versus urokinase for local thrombolysis of femoropopliteal occlusions:
a prospective, randomized multicenter trial. J Endovasc Ther 2001;8:638e47.
9. Risius B, Graor RA, Geisinger MA, Zelch MG, Lucas FV, Young JR, et al.
Recombinant human tissue-type plasminogen activator for thrombolysis in
peripheral arteries and bypass grafts. Radiology 1986;160:183e8.
10. Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. Rev Car-
diovasc Med 2002;3(Suppl. 2):S2e6.
11. Khosla S, Jain P, Manda R, Razminia M, Guerrero M, Trivedi A, et al. Acute and
long-term results after intra-arterial thrombolysis of occluded lower extremity
bypass grafts using recombinant tissue plasminogen activator for acute limb-
threatening ischemia. Am J Ther 2003;10(1):2e6.
12. Schanzer A, Hevelone N, Owens CD, Belkin M, Bandyk DF, Clowes AW, et al.
Technical factors affecting autogenous vein graft failure: observations from
a large multicenter trial. J Vasc Surg 2007;46(6):1180e90 (discussion 1190).
13. Smeets L, Ho GH, Tangelder MJ, Algra A, Lawson JA, Eikelboom BC, et al.
Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study:
comparison of amputation rate in venous and prosthetic grafts. Eur J Vasc
Endovasc Surg 2005;30(6):604e9.
14. Jackson MR, Belott TP, Dickason T, Kaiser WJ, Modrall JG, Valentine RJ, et al. The
consequences of a failed femoropopliteal bypass grafting: comparison of
saphenous vein and PTFE grafts. J Vasc Surg 2000;32(3):498e504. 504e5.
15. Nehler MR, Mueller RJ, McLafferty RB, Johnson SP, Nussbaum JD, Mattos MA, et al.
Outcome of catheter-directed thrombolysis for lower extremity arterial bypass
occlusion. J Vasc Surg 2003;37(1):72e7.
16. Conrad MF, Shepard AD, Rubinfeld IS, Burke MW, Nypaver TJ, Reddy DJ, et al.
Long-term results of catheter-directed thrombolysis to treat infrainguinal
bypass graft occlusion: the urokinase era. J Vasc Surg 2003;37:1009e16.
17. van Holten J, van Dijk LC, van Sambeek MR, van Urk H, van Overhagen H,
Pattynama PM. Thrombolysis of occluded synthetic bypass grafts in the lower
limb: technical success and 1-year follow-up in 32 patients. J Endovasc Ther
2003;10:81e5.
18. Zuckerman DA, Alderman MG, Idso MC, Pilgram TK, Sicard GA. Follow-up of
infrainguinal graft thrombolysis. Arch Surg 2003;138:198e202.
19. Berkowitz HD, Kee JC. Occluded infrainguinal grafts: when to choose lytic
therapy versus a new bypass graft. Am J Surg 1995;170(2):136e9.
20. Pedersen G, Laxdal E, Aune S. The outcome of occluded above-knee femo-
ropopliteal prostheses implanted for critical ischaemia. Eur J Vasc Endovasc Surg
2006;32(6):680e5.
21. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL,
et al. The relative importance of graft surveillance and warfarin therapy in
infrainguinal prosthetic bypass failure. J Vasc Surg 2007;46(6):1160e6.
22. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al.
Mortality over a period of 10 years in patients with peripheral arterial disease.
N Engl J Med 1992;326(6):381e6.
